Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD Study of Lucid-21-302 in Healthy Volunteers
NCT05821387Phase 1Completed
- Sponsor
- Quantum BioPharma Ltd.
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing Lucid-21-302 with Placebo (2 arms). Primary endpoints: Single Dose Safety Outcome Measures up to 12 days, AUC from time zero to the last non-zero concentration after single dose and 8 more. Started Mar 2023; status: completed.
02
Drugs
Lucid-MS
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05821387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821387.